Literature DB >> 1851513

Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease.

G Bellomo1, L Santambrogio, M Fiacconi, A M Scarponi, G Ciuffetti.   

Abstract

Plasma profiles of prolactin, growth hormone, adrenocorticotropic hormone (ACTH) and cortisol were evaluated in a group of untreated patients with idiopathic Parkinson's disease and a group of healthy age-matched controls. Plasma integrated concentrations of all hormones except prolactin were significantly lower in the patients as compared with the controls; however, prolactin nocturnal peak concentration was significantly elevated in the patients; nocturnal growth hormone levels were significantly reduced in the Parkinson group; ACTH and cortisol plasma concentrations were also consistently lower during most of the day in the patients with Parkinson's disease. These data confirm the presence of a hypothalamic disturbance in patients with idiopathic Parkinson's disease, which can affect pituitary function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851513     DOI: 10.1007/bf00319704

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

1.  Food-induced cortisol secretion is mediated by central alpha-1 adrenoceptor modulation of pituitary ACTH secretion.

Authors:  S Al-Damluji; T Iveson; J M Thomas; D J Pendlebury; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1987-05       Impact factor: 3.478

2.  Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.

Authors:  H P Vogel; R Ketsche
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

3.  Effect of apomorphine on growth hormone release in humans.

Authors:  W A Brown; M H Van Woert; L M Ambani
Journal:  J Clin Endocrinol Metab       Date:  1973-09       Impact factor: 5.958

Review 4.  Pharmacology of neural pathways affecting CRH secretion.

Authors:  M T Jones; B Gillham; E A Campbell; A R Al-Taher; T T Chuang; A Di Sciullo
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications.

Authors:  D J Ewing; I W Campbell; B F Clarke
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

6.  The effect of peripheral catecholamine concentrations on the pituitary-adrenal response to corticotrophin releasing factor in man.

Authors:  S R Milsom; R A Donald; E A Espiner; M G Nicholls; J H Livesey
Journal:  Clin Endocrinol (Oxf)       Date:  1986-09       Impact factor: 3.478

7.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

Review 8.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

9.  Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea.

Authors:  L Murri; A Iudice; A Muratorio; A Polleri; T Barreca; G Murialdo
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

10.  Prolactin secretion in Parkinson disease.

Authors:  T Eisler; M O Thorner; R M MacLeod; D L Kaiser; D B Calne
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

View more
  18 in total

Review 1.  Musculoskeletal problems in Parkinson's disease.

Authors:  Young Eun Kim; Beom S Jeon
Journal:  J Neural Transm (Vienna)       Date:  2013-02-19       Impact factor: 3.575

2.  MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.

Authors:  Mauricio P Cunha; Francis L Pazini; Vicente Lieberknecht; Josiane Budni; Ágatha Oliveira; Júlia M Rosa; Gianni Mancini; Leidiane Mazzardo; André R Colla; Marina C Leite; Adair R S Santos; Daniel F Martins; Andreza F de Bem; Carlos Alberto S Gonçalves; Marcelo Farina; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2016-10-08       Impact factor: 5.590

3.  Psychological Stress Phenocopies Brain Mitochondrial Dysfunction and Motor Deficits as Observed in a Parkinsonian Rat Model.

Authors:  Mariana Grigoruţă; Alejandro Martínez-Martínez; Raul Y Dagda; Ruben K Dagda
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

4.  Parkinson's disease and osteoporosis: basic and clinical implications.

Authors:  Carolina A Figueroa; Clifford J Rosen
Journal:  Expert Rev Endocrinol Metab       Date:  2020-04-26

5.  Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson's disease: a systematic review.

Authors:  Nayron Medeiros Soares; Gabriela Magalhães Pereira; Vivian Altmann; Rosa Maria Martins de Almeida; Carlos R M Rieder
Journal:  J Neural Transm (Vienna)       Date:  2018-10-29       Impact factor: 3.575

6.  Bladder, bowel, and sexual dysfunction in Parkinson's disease.

Authors:  Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Fuyuki Tateno; Tomoyuki Uchiyama; Tatsuya Yamamoto; Tomonori Yamanishi
Journal:  Parkinsons Dis       Date:  2011-09-12

7.  Diurnal salivary cortisol concentrations in Parkinson's disease: increased total secretion and morning cortisol concentrations.

Authors:  O Skogar; P-A Fall; G Hallgren; J Lökk; B Bringer; M Carlsson; U Lennartsson; H Sandbjork; C-J Törnhage
Journal:  Int J Gen Med       Date:  2011-08-10

Review 8.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

9.  Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease.

Authors:  Jacob S Daniel; Jyothish P Govindan; Chandan Kamath; Charles D'Souza; Mohamed A Adlan; Lakdasa D Premawardhana
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2014-05-01

10.  Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson's disease patients.

Authors:  Qiang Wei; Honghao Wang; Yanghua Tian; Fangcheng Xu; Xianwen Chen; Kai Wang
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.